Sigilon Therapeutics

Martha Rook, Ph.D., Chief Technical Operations Officer

Oct. 13 | 2:30pm | AVROBIO Ballroom

Cambridge, MA

(NASDAQ: SGTX)

In-person Presentation

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes, or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases, and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis.

www.sigilon.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions